

# Contents

---

	List of Principal Contributors	xi
	Preface <i>RH Hunt, GNJ Tytgat</i>	xix
	<b>Section I. <i>Helicobacter pylori</i> – THE ORGANISM</b>	
1	New <i>Helicobacter</i> species <i>A Lee, B Robertson</i>	3
2	The origin of virulence in type I strains of <i>Helicobacter pylori</i> <i>A Covacci, S Censini, C Lange, M Marchetti, S Guidotti, M Stein, R Rappuoli</i>	13
3	<i>vacA</i> polymorphism <i>JC Atherton</i>	19
4	The interaction of <i>cag</i> <sup>+</sup> <i>Helicobacter pylori</i> strains with their hosts <i>MJ Blaser</i>	27
5	Molecular mimicry between <i>Helicobacter pylori</i> and the host <i>BJ Appelmelk, S Straver, T Verboom, EJ Kuipers, D Claeys, G Faller, T Kirchner, R Negrini, S Krakowka, JJHHM De Pont, I Simoons-Smit, JJ Maaskant, CMJE Vandenbroucke-Grauls</i>	33
6	Considerations of virulence by <i>Helicobacter pylori</i> <i>MJ Blaser</i>	43
	<b>Section II. <i>Helicobacter pylori</i> – TRANSMISSION</b>	
7	The faecal–oral route – a critical look <i>F Mégraud, N Broutet</i>	51
8	<i>Helicobacter pylori</i> : oro–oral, oro–gastric transmission: a critical look at the evidence <i>AE Duggan, RPH Logan</i>	58

- 9 Vectors for the transmission of *Helicobacter pylori*  
DR Cave, P Grübel, L Huang 68

**Section III. *Helicobacter pylori* – INFLAMMATION**

- 10 The host cell response to *Helicobacter pylori* attachment  
LS Tompkins, E Segal, S Falkow 77
- 11 Changes in intracellular signalling following *Helicobacter pylori*  
infection of gastric epithelial cells  
NL Jones, PM Sherman 84
- 12 *Helicobacter pylori* – interactions with phagocytes  
M Chmiela, B Paziak-Domanska, S Hirno, W Rudnicka,  
M Utt, T Wadström 90
- 13 Th<sub>1</sub>/Th<sub>2</sub> lymphocyte responses in *Helicobacter* infections  
JG Nedrud, M Mohammadi, T Blanchard, R Redline, SJ Czinn 101
- 14 Epithelial cell turnover and apoptosis  
SF Moss 110
- 15 Cytokine-enhanced, *Helicobacter pylori*-induced, epithelial  
cell apoptosis  
PB Ernst, VE Reyes, X-J Fan, SE Crowe 123

**Section IV. *Helicobacter pylori* – FUNCTIONAL SECRETORY  
AND MOTOR DISTURBANCES**

- 16 Acid-adaptive mechanisms of gastric *Helicobacter*  
D Scott, D Weeks, M Rektorschek, G Sachs, K. Melchers 133
- 17 *Helicobacter pylori* and gastroduodenal secretions  
L Olbe, A Hamlet, L Fändriks 148
- 18 Relevant factors in regulating endocrine, parietal and chief cells  
DR Cave, N Masubuchi, PJ Goddard 158
- 19 Histamine and *Helicobacter pylori*: are we closer to the answer?  
J Calam, P Bliss, S Murray, G Taylor 169
- 20 The effect of *Helicobacter pylori* on enterochromaffin-like (ECL)  
cell function  
IM Modlin, M Kidd, K Miu, LH Tang 176

## CONTENTS

21	Mast cells and duodenal bicarbonate secretion <i>KE Barrett, CP Myers, D Hogan, V Pratha, JI Isenberg</i>	188
22	The impact of <i>Helicobacter pylori</i> infection on gastric neuromuscular function in the rat: basic observations and clinical implications for our understanding of functional dyspepsia <i>SM Collins, B Blennerhassett, R DeGiorgio, G Barbara, G Tougas, H Li, H Larsson</i>	195
<b>Section V: <i>Helicobacter pylori</i> – PATHOLOGICAL ASPECTS</b>		
23	What drives the pattern of activity of the inflammatory reaction? Differences in antrum and corpus <i>AB Price</i>	209
24	Defining atrophic gastritis and grading gastric atrophy: new challenges beyond the Sydney System <i>RM Genta</i>	215
25	Cardia mucosa gastritis (carditis): pathogenesis, correlation with gastritis of other sites and clinicopathological relevance <i>E Solcia, L. Villani, E Trespi, F Brogna, C Colla, O Luinetti, L. Mastracci, C Tinelli, F Fiocca</i>	224
<b>Section VI: CLINICAL ASPECTS OF <i>Helicobacter pylori</i> INFECTION</b>		
26	<i>Helicobacter pylori</i> and non-ulcer dyspepsia – a critical look <i>SJO Veldhuyzen Van Zanten</i>	235
27	Implications of <i>Helicobacter pylori</i> : ‘test-and-treat’ approach in a primary-care setting <i>DA Peura</i>	245
28	Prerequisites of an adequate approach to dyspepsia: differences between the west and the east <i>SK Lam</i>	252
29	The <i>Helicobacter pylori</i> –non-steroidal anti-inflammatory drug interaction: consensus at last? <i>MB Fennerty</i>	260
30	<i>Helicobacter pylori</i> infection and coronary heart disease: a critical look <i>J Danesh</i>	267
31	Pitfalls in <i>Helicobacter pylori</i> diagnosis <i>P Malfertheiner, C Gerards, A Leodolter, M Nilius</i>	274

**Section VII. *Helicobacter pylori*-ASSOCIATED GASTRIC CANCER AND LYMPHOMA**

32	An overview of <i>Helicobacter pylori</i> epidemiology studies <i>J-Q Huang, RH Hunt</i>	295
33	Nitrogen oxides and the gastric precancerous process <i>MJS Miller, P Correa</i>	308
34	<i>Helicobacter pylori</i> -associated gastric cancer: is population-based screening and therapy realistic? <i>GNJ Tytgat</i>	315
35	Gastric carcinogenesis: when is the point of no return? <i>NA Wright</i>	325
36	Atrophy, metaplasia and dysplasia – a risk for gastric cancer: are they reversible? <i>MF Dixon</i>	336
37	Lessons from ongoing intervention studies <i>D Forman</i>	354
38	Criteria for the diagnosis of mucosa-associated lymphoid tissue lymphoma <i>AC Wotherspoon</i>	362
39	Early and long-term results of <i>Helicobacter pylori</i> cure of MALT lymphoma – what are the pitfalls? <i>M Stolte, A Morgner, A Meining, Ch Thiede, Th Wündisch, E Bayerdörffer, A Neubauer</i>	373

**Section VIII. *Helicobacter pylori* – TREATMENT ISSUES**

40	Nitroimidazole metabolism and resistance in <i>Helicobacter pylori</i> <i>DI Edwards</i>	383
41	Bioavailability of antimicrobials after oral and parenteral administration <i>AF Goddard, PV Sherwood</i>	392
42	Antimicrobial resistance in <i>Helicobacter pylori</i> : a global overview <i>Y Glupczynski</i>	398
43	Does bismuth prevent antimicrobial resistance of <i>Helicobacter pylori</i> ? <i>R Williamson, GA Pipkin</i>	416

## CONTENTS

44	Variability in the outcome of treatment of <i>Helicobacter pylori</i> infection: a critical analysis <i>DY Graham, MP Dore</i>	426
45	Novel therapies for <i>Helicobacter pylori</i> eradication <i>S Montague and C O'Morain</i>	441
46	Towards monotherapy – what progress? First results with a new single 'triple' capsule <i>WA de Boer</i>	456
47	Towards vaccination: what progress? <i>A Lee, P Sutton, C Doidge</i>	462
<b>Section IX. THE FUTURE OF <i>Helicobacter pylori</i> RESEARCH</b>		
48	The future of <i>Helicobacter pylori</i> research: the agenda for microbiologists <i>A Lee</i>	473
49	The future of <i>Helicobacter pylori</i> research: the agenda for histopathologists <i>MF Dixon, FA Lewis</i>	483
50	<i>Helicobacter pylori</i> : the clinical agenda <i>JW Freston</i>	490
	Index	499